Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their… Read more »
xCures News Collection
xCures and Novocure® partner to better understand quality of life in glioblastoma
Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance… Read more »
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/ Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access… Read more »
xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records
Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer. xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with… Read more »
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence,… Read more »
xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®
Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The… Read more »
xCures and BioSpark partner to boost Real World Oncology Data offerings
New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and… Read more »
TARGET: Cancer Podcast to be hosted by media personality Dr. Sanjay Juneja – TheOncDoc
Oncologist and cancer educator Dr. Sanjay Juneja will host xCures’ informative podcast on cancer and technology February 17, 2022 – Oakland, CA. – xCures, a direct-to-patient, and direct-to-physician oncology platform, is proud to announce Sanjay Juneja, MD, as the host to their TARGET: Cancer podcast. Dr. Sanjay Juneja is a leading oncologist… Read more »
